New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation / 医学前沿
Frontiers of Medicine
; (4): 17-24, 2022.
Article
in En
| WPRIM
| ID: wpr-929201
Responsible library:
WPRO
ABSTRACT
Obesity is an important risk factor of type 2 diabetes (T2D), which has become an important factor threatening human health. However, no perfect drug choice for obesity exists. Semaglutide is a kind of human glucagon-like peptide-1 (GLP-1) analog that promotes insulin secretion while inhibiting glucagon secretion through a glucose concentration-dependent mechanism. GLP-1 can also delay stomach emptying and suppress appetite to help lose weight. This review summarizes clinical evidence of the semaglutide effect on T2D and obesity and establishes expectations on future clinical trials for obesity treatment.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Diabetes Mellitus, Type 2
/
Glucagon-Like Peptides
/
Glucagon-Like Peptide-1 Receptor
/
Hypoglycemic Agents
/
Motivation
/
Obesity
Type of study:
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Frontiers of Medicine
Year:
2022
Type:
Article